Ceftriaxone
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A third-generation cephalosporin with broad-spectrum activity against many gram-negative and gram-positive organisms. Administered parenterally (IM or IV), it is a cornerstone agent for community-acquired pneumonia, bacterial meningitis, gonorrhea, acute bacterial otitis media (when oral therapy fails), pelvic inflammatory disease, intra-abdominal infections, and complicated urinary tract infections. Its long half-life allows once-daily dosing.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A third-generation cephalosporin with broad-spectrum activity against many gram-negative and gram-positive organisms. NutriStack rates the supporting evidence as strong. Common adult dosing is 1-2 g IV/IM once daily; meningitis: 2 g IV every 12 hours; gonorrhea: 500 mg IM single dose (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete vitamin k. This profile indexes 10 sources.
- Diarrhea
- Injection site pain (IM)
- Rash
- Known cephalosporin or severe penicillin allergy (anaphylaxis)
- Neonates with hyperbilirubinemia (displaces bilirubin from albumin)4
The bottom line
Evidence rating strong. Most-documented uses: treats community-acquired pneumonia, treats bacterial meningitis, treats gonorrhea (recommended im regimen). 10 sources indexed (2012–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Binds to penicillin-binding proteins (PBPs), disrupting the transpeptidation step of peptidoglycan cell wall synthesis. Third-generation cephalosporins are highly resistant to many beta-lactamases and have enhanced penetration through gram-negative outer membrane porin channels, resulting in potent gram-negative activity including against N. meningitidis, H. influenzae, and many Enterobacteriaceae. Achieves therapeutic CSF concentrations when meninges are inflamed.
Dosing & protocol.
Administered parenterally (IV or IM). 100% bioavailable by IM route. Not available in oral formulation. Widely distributed including to CSF when meninges are inflamed.
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Vitamin K
MildBroad-spectrum antibiotic exposure can suppress gut bacteria that synthesize menaquinones, lowering vitamin K availability in susceptible patients.
Full safety detail.
Side effects
- Diarrhea
- Injection site pain (IM)
- Rash
- Eosinophilia
- Biliary sludging/pseudolithiasis (especially in children)
- Elevated liver enzymes
- Clostridioides difficile-associated diarrhea
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
6- 1Ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections is associated with increased short-term mortality: a systematic review and meta-analysisPMIDMaraolo AE, Nobile M, Gentile I · Annals of medicine · 2026
Maraolo AE, Nobile M, Gentile I. Ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections is associated with increased short-term mortality: a systematic review and meta-analysis. Annals of medicine. 2026
- 2Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic reviewPMIDComce MH, Weersink RA, Beuers U et al. · The Journal of antimicrobial chemotherapy · 2024
Comce MH, Weersink RA, Beuers U et al.. Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review. The Journal of antimicrobial chemotherapy. 2024
- 3Safety of ceftriaxone in paediatrics: a systematic reviewPMIDZeng L, Wang C, Jiang M et al. · Archives of disease in childhood · 2020
Zeng L, Wang C, Jiang M et al.. Safety of ceftriaxone in paediatrics: a systematic review. Archives of disease in childhood. 2020
- 4Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the LiteraturePMIDDonnelly PC, Sutich RM, Easton R et al. · Paediatric drugs · 2017
Donnelly PC, Sutich RM, Easton R et al.. Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatric drugs. 2017
- 5Safety of ceftriaxone in paediatrics: a systematic review protocolPMIDZeng L, Choonara I, Zhang L et al. · BMJ open · 2017
Zeng L, Choonara I, Zhang L et al.. Safety of ceftriaxone in paediatrics: a systematic review protocol. BMJ open. 2017
- 6Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trialsPMIDBai ZG, Bao XJ, Cheng WD et al. · International journal of STD & AIDS · 2012
Bai ZG, Bao XJ, Cheng WD et al.. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. International journal of STD & AIDS. 2012
Reference material
4- 7Tunkel AR et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004.Source linkedPMID
- 8Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007.Source linkedPMID
- 9St Cyr S et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR. 2020.Source linkedPMID
- 10Richards DM, Heel RC, Brogden RN et al.. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984Source linkedPMID
Common questions.
Quick answers about Ceftriaxone, drawn from the data on this page.
What is Ceftriaxone?
A third-generation cephalosporin with broad-spectrum activity against many gram-negative and gram-positive organisms. Administered parenterally (IM or IV), it is a cornerstone agent for community-acquired pneumonia, bacterial meningitis, gonorrhea, acute bacterial otitis media (when oral therapy fails), pelvic inflammatory disease, intra-abdominal infections, and complicated urinary tract infections. Its long half-life allows once-daily dosing.
What is Ceftriaxone used for?
Commonly cited benefits of Ceftriaxone include: Treats community-acquired pneumonia; Treats bacterial meningitis; Treats gonorrhea (recommended IM regimen); Treats complicated urinary tract infections and pyelonephritis; Treats intra-abdominal infections (with metronidazole). NutriStack rates the overall evidence as strong.
What is a typical dose of Ceftriaxone?
A typical adult dose of Ceftriaxone is 1-2 g IV/IM once daily; meningitis: 2 g IV every 12 hours; gonorrhea: 500 mg IM single dose (as prescribed by your physician). The commonly recommended form is IV or IM injection only. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Ceftriaxone?
Reported side effects include diarrhea, injection site pain (im), rash, eosinophilia, biliary sludging/pseudolithiasis (especially in children), elevated liver enzymes. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Ceftriaxone?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Ceftriaxone in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.